Clinical Trials Directory

Trials / Completed

CompletedNCT00561236

Does Intravitreal Injection of Triamcinolone Acetonide Impairs the Adrenal Function

Low Dose (1mcg ) ACTH Stimulation Test for Assessment of the Hypothalamo- Pituitary- Adrenal Axis in Patients Treated With Intravitreal Injection of Triamcinolone Acetonide

Status
Completed
Phase
Study type
Observational
Enrollment
28 (actual)
Sponsor
HaEmek Medical Center, Israel · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

The use of intravitreal corticosteroids in the management ocular inflammatory diseases has recently gained widespread acceptance. The purpose of this study is to determine if the use of intravitreal triamcinolone is associated with suppression of endogenous cortisol production, as generally admitted for patients treated with oral or parenteral corticosteroid therapy.

Detailed description

The normalcy of hypothalamic- pituitary- adrenal axis (HPA axis) of enrolled subjects will will be assessed before intravitreal injection of 4mg of triamcinolone and again after one day, one week and two weeks. Patients with abnormal HPA axis will be re-tested after four weeks and later until the HPA axis function return to normal. The HPA axis will be assessed with low dose (1mcg) intravenous corticotropin(ACTH) stimulation test, in which cortisol levels will be sampled before , 30 minutes and 60 minutes after 1mcg ACTH IV injection.

Conditions

Timeline

Start date
2007-04-01
Primary completion
2007-12-01
Completion
2008-01-01
First posted
2007-11-20
Last updated
2016-09-08

Locations

1 site across 1 country: Israel

Source: ClinicalTrials.gov record NCT00561236. Inclusion in this directory is not an endorsement.

Does Intravitreal Injection of Triamcinolone Acetonide Impairs the Adrenal Function (NCT00561236) · Clinical Trials Directory